Healio6 天
Brentuximab vedotin regimen extends OS in heavily pretreated DLBCL
The addition of brentuximab vedotin to lenalidomide and rituximab extended survival among heavily pretreated patients with ...
Targeted Oncology10 天
Updated Findings on Datopotamab Deruxtecan in Urothelial Cancer Treatment
Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily ...